07:00 , Jul 20, 2009 |  BC Week In Review  |  Clinical News

Fluidosomes tobramycin regulatory update

FDA granted Orphan Drug designation for Axentis' Fluidsomes tobramycin to treat pulmonary infections caused by Burkholderia cepacia in patients with cystic fibrosis (CF). The inhalable liposomal formulation of tobramycin already has Orphan designation in the...
07:00 , May 11, 2009 |  BC Week In Review  |  Clinical News

Fluidosomes Tobramycin regulatory update

FDA granted Orphan Drug designation for Axentis' Fluidosomes Tobramycin to treat pulmonary infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis (CF). The fluid liposomal-tobramycin formulation is in Phase II testing for the indication....
07:00 , Sep 8, 2008 |  BC Week In Review  |  Clinical News

Fluidosomes Tobramycin: Phase IIa started

Axentis began an international Phase IIa trial to evaluate 2 dosages of ARB-CF0223 in 24 patients with CF. The company licensed the product, which has European Orphan designation for the indication, from aRigen in December...
07:00 , Jun 30, 2008 |  BC Week In Review  |  Company News

Axentis, BioDevelops deal

Axentis acquired BioDevelops Pharma for an undisclosed amount. The acquisition gave Axentis exclusive rights to IP covering the use of molecules for the enzymatic removal of ubiquitin markers from incorrectly folded proteins. The company plans...